This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arpino, G. Articles by Schiff, R. Search for Related Content PubMed PubMed Citation Articles by Arpino, G. Articles by Schiff, R.

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

Lester and Sue Smith Breast Center (L.W., C.K.O., R.S.), and the Dan L. Duncan Cancer Center (G.A., L.W., C.K.O., R.S.), the Department of Medicine (G.A., L.W., C.K.O., R.S.), and the Department of Molecular and Cellular Biology (C.K.O., R.S.), Baylor College of Medicine, Houston, Texas 77030

Correspondence: Address all correspondence and requests for reprints to: Rachel Schiff, Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, Texas 77030. E-mail: rschiff{at}bcm.tmc.edu

Breast cancer evolution and tumor progression are governed by the complex interactions between steroid receptor [estrogen receptor (ER) and progesterone receptor] and growth factor receptor signaling. In recent years, the field of cancer therapy has witnessed the emergence of multiple strategies targeting these specific cancer pathways and key molecules (ER and growth factor receptors) to arrest tumor growth and achieve tumor eradication; treatment success, however, has varied and both de novo (up front) and acquired resistance have proven a challenge. Recent studies of ER biology have revealed new insights into ER action in breast cancer and have highlighted the role of an intimate crosstalk between the ER and HER family signaling pathways as a fundamental contributor to the development of resistance to endocrine therapies against the ER pathway. The aim of this review article is to summarize the current knowledge on mechanisms of resistance of breast cancer cells to endocrine therapies due to the crosstalk between the ER and the HER growth factor receptor signaling pathways and to explore new available therapeutic strategies that could prolong duration of response and circumvent endocrine resistant tumor growth.

This article has been cited by other articles:

				G. Sabnis, O. Goloubeva, R. Gilani, L. Macedo, and A. Brodie Sensitivity to the Aromatase Inhibitor Letrozole Is Prolonged After a "Break" in Treatment Mol. Cancer Ther., January 1, 2010; 9(1): 46 - 56. [Abstract] [Full Text] [PDF]

				S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5538 - 5546. [Abstract] [Full Text] [PDF]

				F. YOTSUMOTO, A. SANUI, T. FUKAMI, K. SHIROTA, S. HORIUCHI, H. TSUJIOKA, T. YOSHIZATO, M. KUROKI, and S. MIYAMOTO Efficacy of Ligand-based Targeting for the EGF System in Cancer Anticancer Res, November 1, 2009; 29(11): 4879 - 4885. [Abstract] [Full Text] [PDF]

				O. Sukocheva, L. Wang, E. Verrier, M. A. Vadas, and P. Xia Restoring Endocrine Response in Breast Cancer Cells by Inhibition of the Sphingosine Kinase-1 Signaling Pathway Endocrinology, October 1, 2009; 150(10): 4484 - 4492. [Abstract] [Full Text] [PDF]

				R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer J. Clin. Oncol., August 20, 2009; 27(24): 3908 - 3915. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Ann. Onc., August 1, 2009; 20(8): 1319 - 1329. [Abstract] [Full Text] [PDF]

				M. J. Higgins and V. Stearns Understanding Resistance to Tamoxifen in Hormone Receptor-Positive Breast Cancer Clin. Chem., August 1, 2009; 55(8): 1453 - 1455. [Full Text] [PDF]

				S. Banerjee, M. Zvelebil, P. Furet, U. Mueller-Vieira, D. B. Evans, M. Dowsett, and L.-A. Martin The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase Cancer Res., June 1, 2009; 69(11): 4716 - 4723. [Abstract] [Full Text] [PDF]

				T. W. Miller, M. Perez-Torres, A. Narasanna, M. Guix, O. Stal, G. Perez-Tenorio, A. M. Gonzalez-Angulo, B. T. Hennessy, G. B. Mills, J. P. Kennedy, et al. Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer Cancer Res., May 15, 2009; 69(10): 4192 - 4201. [Abstract] [Full Text] [PDF]

				T. A. Rose-Hellekant, A. J. Skildum, O. Zhdankin, A. L. Greene, R. R. Regal, K. D. Kundel, and D. W. Kundel Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors Cancer Prevention Research, May 1, 2009; 2(5): 496 - 502. [Abstract] [Full Text] [PDF]

				S Badve and H Nakshatri Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications J. Clin. Pathol., January 1, 2009; 62(1): 6 - 12. [Abstract] [Full Text] [PDF]